Enoblituzumab, previously known as TJ-271 or MGA271, represents a novel monoclonal directed at CD33, an antigen found predominantly on myeloid tissues. Such antibody functions as a dual-action therapy, simultaneously https://www.targetmol.com/compound/enoblituzumab